Mr. Chair, the goal with the pilot plant would have been to be able to produce, for emergency use under emergency use authorization, something in the range of 100,000 to 200,000 doses per month if that could have been pursued. Obviously, that wasn't the position we were in last November, so obviously we will have that capacity and capability on an ongoing basis, but I can't reverse how the course of events occurred over the summer and into the fall. Again, there are certainly some very clear reasons as to why that was not necessarily the kind of opportunity that was going to attract one of the larger global-scale vaccine producers.
On February 22nd, 2021. See this statement in context.